Occupier

Find Out The Latest

Keep in touch with news and developments from The Oxford Science Park and its occupiers here.

You can also follow us on LinkedIn

Novo Holdings invests in Oxford Nanopore Technologies

01 Aug 2025

Novo Holdings, a leading international life science investor, today announced a £50m investment in Oxford Nanopore Technologies, the leading UK Listed company behind a new generation of molecular sensing technology based on nanopores, located at The Oxford Science Park. Novo Holdings will invest £50m in Oxford Nanopore as part of an equity issue and intends to add to this investment over time, with further purchases in the secondary market,... Read more

Approval for first-in-human trial of nerve regeneration technology using spider silk

27 Jul 2025

Newrotex, based at The Oxford Science Park, has received regulatory approval for its first-in-human clinical trial of SilkAxons™, an advanced bioengineered nerve guide which uses the silk of spiders to repair severe peripheral nerve injuries. The trial will be conducted at The Panama Clinic in Panama City, with bioaccess®, Latin America’s leading first-in-human contract research organisation (CRO), managing regulatory and clinical... Read more

Improved outcomes in late-stage skin cancer revealed by new Scancell data

23 Jul 2025

Scancell, a clinical stage biotechnology company based at The Oxford Science Park, has announced further positive data from its ongoing Phase 2 SCOPE trial of immunotherapies targeting advanced tumours that cannot be removed surgically. The overall response rate to iSCIB1+, a modified version of Scancell’s lead product (SCIB1) from its DNA Immunobody® platform, was 69% for target HLA type patients, representing 80% of total patients - greatly... Read more

Evox Therapeutics Expands Scientific Advisory Board

18 Jul 2025

Evox Therapeutics Ltd, a biotechnology company developing innovative therapies for rare, genetically driven neurodegenerative diseases using a next-generation gene editing modality, today announced the appointment of three world-class scientists to its Scientific Advisory Board (SAB). These appointments come as Evox advances a focused pipeline of transformative gene editing therapies targeting the MSH3 gene for the treatment of Huntington’s... Read more

Ochre Bio appoints Quin Wills as CEO

02 Jul 2025

Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease based at The Oxford Science Park, has appointed Dr Quin Wills as CEO. As Founder of Ochre Bio, and previously CSO, Quin has been driving the company’s innovative approach to late-stage liver disease, developing potential new therapeutics to target disease progression. Quin will now lead the company in the next phase of its ambitions: progressing new drug... Read more

News